These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Cui Z; Lockman PR; Atwood CS; Hsu CH; Gupte A; Allen DD; Mumper RJ Eur J Pharm Biopharm; 2005 Feb; 59(2):263-72. PubMed ID: 15661498 [TBL] [Abstract][Full Text] [Related]
3. Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine. Rossi L; Squitti R; Pasqualetti P; Marchese E; Cassetta E; Forastiere E; Rotilio G; Rossini PM; Finazzi-Agró A Neurosci Lett; 2002 Aug; 329(2):137-40. PubMed ID: 12165396 [TBL] [Abstract][Full Text] [Related]
4. Trace element alterations in Alzheimer's disease: A review. Cilliers K Clin Anat; 2021 Jul; 34(5):766-773. PubMed ID: 33580904 [TBL] [Abstract][Full Text] [Related]
5. Metals in Alzheimer's disease: a systemic perspective. Squitti R Front Biosci (Landmark Ed); 2012 Jan; 17(2):451-72. PubMed ID: 22201755 [TBL] [Abstract][Full Text] [Related]
6. Role of metal dyshomeostasis in Alzheimer's disease. Bonda DJ; Lee HG; Blair JA; Zhu X; Perry G; Smith MA Metallomics; 2011 Mar; 3(3):267-70. PubMed ID: 21298161 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W; Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331 [TBL] [Abstract][Full Text] [Related]
8. Current status of metals as therapeutic targets in Alzheimer's disease. Finefrock AE; Bush AI; Doraiswamy PM J Am Geriatr Soc; 2003 Aug; 51(8):1143-8. PubMed ID: 12890080 [TBL] [Abstract][Full Text] [Related]
10. Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. Kessler H; Pajonk FG; Bach D; Schneider-Axmann T; Falkai P; Herrmann W; Multhaup G; Wiltfang J; Schäfer S; Wirths O; Bayer TA J Neural Transm (Vienna); 2008 Dec; 115(12):1651-9. PubMed ID: 18972062 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA; Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517 [TBL] [Abstract][Full Text] [Related]
12. Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Schrag M; Mueller C; Oyoyo U; Smith MA; Kirsch WM Prog Neurobiol; 2011 Aug; 94(3):296-306. PubMed ID: 21600264 [TBL] [Abstract][Full Text] [Related]
13. Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. Chen SJ; Kuo CC; Pan HY; Tsou TC; Yeh SC; Chang JY Biochem Pharmacol; 2015 May; 95(1):28-37. PubMed ID: 25801007 [TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease treated patients showed different patterns for oxidative stress and inflammation markers. Gubandru M; Margina D; Tsitsimpikou C; Goutzourelas N; Tsarouhas K; Ilie M; Tsatsakis AM; Kouretas D Food Chem Toxicol; 2013 Nov; 61():209-14. PubMed ID: 23871825 [TBL] [Abstract][Full Text] [Related]
15. Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. Cherny RA; Barnham KJ; Lynch T; Volitakis I; Li QX; McLean CA; Multhaup G; Beyreuther K; Tanzi RE; Masters CL; Bush AI J Struct Biol; 2000 Jun; 130(2-3):209-16. PubMed ID: 10940226 [TBL] [Abstract][Full Text] [Related]